Coronary artery diseaseComparison of the Predictive Value of Four Different Risk Scores for Outcomes of Patients With ST-Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Section snippets
Methods
From January 2001 to June 2006, a total of 974 consecutive patients with STEMI undergoing emergency primary percutaneous coronary intervention at the Rabin Medical Center, Israel, were prospectively followed up and entered into a clinical database. Acute STEMI was defined as the presence of typical chest pain and accompanying symptoms for ≥30 minutes but <12 hours in the presence of ST-segment elevation ≥1 mm in ≥2 contiguous leads or new or undetermined duration of left branch bundle block in
Results
A total of 855 patients with STEMI were included in the study. Baseline characteristics and medications used by patients before admission are listed in Table 2. It should be noted that aspirin and clopidogrel may have been administered in the emergency department before admission. At 30 days, 27 patients (3.2%) developed reinfarction, stent thrombosis occurred in 19 patients (2.2%), 24 patients (2.8%) underwent target-vessel revascularization, 31 patients died (mortality rate 3.6%), and a major
Discussion
The present study, based on a large registry of consecutive patients with STEMI treated using primary percutaneous coronary intervention, compared the predictive accuracy of 4 different risk scores for clinical outcomes at 30 days and 1 year. We found that the CADILLAC, TIMI, and PAMI risk scores all had relatively high predictive value for mortality at 1 and 12 months, with slight superiority of the CADILLAC score. The GRACE score did not perform as well and had a low prognostic value.
Accurate
References (14)
- et al.
Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials
Lancet
(2003) - et al.
Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score
J Am Coll Cardiol
(2005) - et al.
Predicting mortality in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention (PAMI risk score)
Am J Cardiol
(2004) - et al.
Predictive value of the Killip classification in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction
Am J Cardiol
(2001) - et al.
Impact and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction
Am J Cardiol
(2005) - et al.
Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial
J Am Coll Cardiol
(2004) - et al.
TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an Intravenous nPA for Treatment of Infarcting Myocardium II trial substudy
Circulation
(2000)
Cited by (105)
Ten-year prognostic impact of target versus non-target vessel failure after STEMI. Insight from the EXAMINATION-EXTEND trial
2024, Revista Espanola de CardiologiaMachine learning-based prediction of infarct size in patients with ST-segment elevation myocardial infarction: A multi-center study
2023, International Journal of CardiologyTemporal Trends of the Management and Outcome of Patients With Myocardial Infarction According to the Risk for Recurrent Cardiovascular Events
2020, American Journal of MedicineCitation Excerpt :Thus, risk stratification is imperative for better management of patients after myocardial infarction.4 A number of cardiovascular risk assessment models have been proposed,13–15 and some have been validated as efficient tools for risk stratification and therapeutic decision making, in the short- and long-term periods after myocardial infarction.1,16–21 The Thrombolysis in Myocardial Infarction (TIMI) risk score for secondary prevention (TRS2°P), based on 9 clinical characteristics, was recently developed to risk-stratify patients that could benefit the most from the anti-thrombotic agent Vorapaxar.22
Prediction of mortality in hospital survivors of STEMI: External validation of a novel acute myocardial infarction prognostic score
2019, Cardiovascular Revascularization MedicineCitation Excerpt :Patients were included in a prospective STEMI registry [16]. The database included detailed demographic, clinical, angiographic and procedural data as previously described by our group [16]. Patients were excluded from the present study if admitted ≥12 h from the onset of symptoms, admitted before or after the latter period, died in-hospital or in case of missing data for SAMI score calculation.